On July 10th, Gelunhui reported that Tianjin Lisheng Pharmaceutical (002393.SZ) recently received the Drug Registration Certificate (Approval No. 2024S01592) issued by the National Medical Products Administration for the sustained-release tablet of 4mg (calculated as C23H25N5O5) of methsuximide hydrochloride. The pharmaceutical product has been approved for marketing.
According to the data provided by the Minet database, in 2022 and 2023, the sales revenue of methsuximide hydrochloride preparations in China are 0.579 billion yuan and 6.38 billion yuan, respectively.